Abstract:Objective To investigate the consensus and controversies on delineation of radiotherapy target volume for patients with non-small cell lung cancer(NSCLC). Methods Study questionnaires were designed by radiation oncologists in Peking University School of Oncology. The forms were sent through email to radiation oncologists in 10 radiation departments in China and 2 departments in US in November,2007. The brief introduction and PET/CT digital data of one patient with NSCLC were sent to radiation oncologists in 10 departments in Beijing. On Jan. 12,2008,the case discussion was held by more than 300 radiation oncologists from Beijing,Tianjin, Hebei, Liaoning Province and Inner Mongolia Autonomous Region. Results All receivers of the questionnaire responded . The set up error was 5-7 mm . For patients with locally advanced NSCLC treated with radiotherapy concurrently with near full dose chemotherapy,ll out ot 12 responding departments defined planning target volume(PTV) of primary tumor as gross tumor volume(GTV) plus 6-8 nun plus set-up error and respiratory movements ,and only one defined PTV as GTV plus set-up error and respiratory movements. For PTV of the mediastinal lymph nodes in the same patient,9 out of 12 responding departments defined PTV as GTV plus 6-8 mm plus set-up error and respiratory movements,and 3( of China) out of 12 defined PTV as GTV plus set-up error and respiratory movements. Stereotactic body .radiotherapy with high fraction dose was used in 11 out of 12 responding departments with fraction dose varying from 6 to 20 Gy,including 6 of which defined PTV of primary tumor as GTV plus 6-8 mm plus respiratory movements and set-up error, and 5 defined PTV of early stage lung cancer as GTV plus respiratory movements and set-up error. The consensus on delineation of primary tumor of the case discussion was that the appropriate window width and window level were 1600 Houasfield Units(HU) and -600 HU for lung window,and 400 HU and 20 HU for mediastinal window. The controversies was focused on whether the CTV for metastatic lymph nodes should be restricted as GTV plus 6-8 mm or enlarged to enclose all the involved lymph node region. Conclusions PIT of primary tumor and mediastinal metastatic lymph nodes should be GTV plus 6-8 mm plus respiratory movements plus set-up error. The basic controversies of target delineation are focused on the fraction dose and PIT range for early stage NSCLC, and on the possibility of defining the PIT as GTV plus respiratory movements and set-up error when treated with concurrent radiotherapy and full dose chemotherapy for locally advanced NSCLC.

[Role of Precision Radiotherapy for the Curable Non-small Cell Lung Cancer.].

Efficacy and Potential MicroRNA Mechanism for Computed Tomography-Guided Percutaneous Radiofrequency Ablation of Primary Lung Cancer and Lung Metastasis from Liver Cancer

Nano-Assisted Radiotherapy Strategies: New Opportunities for Treatment of Non-Small Cell Lung Cancer

[Minimally Invasive Therapies for Early Stage Non-small Cell Lung Cancer].

Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine

Curative Radiotherapy of Early Operable Non-Small Cell Lung Cancer.

Advancements in radiotherapy for lung cancer in China

Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer.

Radionuclide-based Theranostics - a Promising Strategy for Lung Cancer.

The Theoretical Foundation and Research Progress for Erlotinib Combined with Whole Brain Radiotherapy for the Treatment for Non-Small Cell Lung Cancer Patients with Brain Metastases

Application of nano-radiosensitizers in non-small cell lung cancer

[New Radiation Therapy Concepts in Non-Metastatic Lung Cancer]

[Clinical developments for the EGFR-TKI combined with radiotherapy in advanced non-small cell lung cancer].

Precision Cancer Medicine: Deliver a Lasting Blow to Cancer!

Consensus and controversies on delineation of radiotherapy target volume for patients with non-small cell lung cancer

The role of radiotherapy and chemotherapy for curative management of medically inoperable and stage III nonsmall cell lung cancer, and radiotherapy for palliation of symptomatic disease

Precision Management of Advanced Non–Small Cell Lung Cancer

International Consensus on Radiotherapy in Metastatic Non-Small Cell Lung Cancer

Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer

The Position and Progress of Rediotherapy in NSCLC

EGFR Inhibitors with Concurrent Thoracic Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer